The metabolic syndrome: Insulin resistance

Current Hypertension Reports

Volumn 11, Issue 2, 2009, Pages 156-158

  Mikhail, Nasser ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ABDOMINAL OBESITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PREDICTION; PREVALENCE; REVIEW;

BODY MASS INDEX; DYSLIPIDEMIAS; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPOLYSIS; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; SODIUM; SYMPATHETIC NERVOUS SYSTEM; WAIST-HIP RATIO;

EID: 62549162196     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0027-4     Document Type: Review

References (26)

1. Kahn R, Buse J, FeTrannini E, Stern M: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2005, 28:2289-2304.
2. Hanley AJG, Wagenknecht LE, D'Agostino RB, et al.: Identification of subjects with insulin resistance and b-cell dysfunction using alternative definitions of the metabolic syndrome 2003, 52:2740-2747.
3. Jeppesen J, Hansen TW, Rasmussen S, et al.: Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease. J Am Coll Cardiol 2007, 49:2112-2119.
4. Yki-Jarvinen H: Glucose toxicity. Endocr Rev 1992, 13:415-431.
5. Del Prato S, Leonetti F, Simonson DC, et al.: Effect of sustained physiologic hyperinsulinemia and hyperglycemia on insulin secretion and insulin sensitivity in man. Diabetologia 1994, 37:1025-1035.
6. Bertaccca A, Ciccarone A, Cecchetti P, et al.: Continually high insulin levels impair Akt phosphorylation and glucose transport in human myoblasts. Metabolism 2005, 54:1687-1693.
7. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365:1415-1428.
8. Ferrannini E, Barrett EJ, Bevilacqua S, De Fronzo RA: Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983, 72:1737-1747.
9. Anderson EA, Hoffman RP, Balon TW, et al.: Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991, 87:2246-2252.
10. Strazzullo P, Barbato A, Galletti F, et al.: Abnormalities in renal sodium handling in the metabolic syndrome. Results of the Oliveti Heart Study. J Hyperten 2006, 24:1633-1639.
11. Barbato A, Cappucio FP, Folkerd EJ, et al.: Metabolic syndrome and renal sodium handling in three ethnic groups living in England. Diabetologia 2004, 47:40-46.
12. Tuck ML, Bounoua F, Eslami P, et al.: Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells. J Hypertens 2004, 22:1779-1785.
13. Fallo F, Veglio F, Bertello C, et al.: Prevalence and characteristics of the metabolic syndrome in primary hyperaldosteronism. J Clin Endocrinol Metab 2006, 91:454-459.
14. Mikhail N, Tuck M: Insulin and the vasculature. Curr Hypertens Rep 2000, 2:148-153.
15. Laasko M, Edelman S, Brechtel G, Baron A: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990, 85:1844-1852.
16. Laasko M, Edelman S, Brechtel G, Baron A: Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 1992, 41:1076-1083.
17. Natali A, Taddei S, Galvan AQ, et al.: Insulin sensitivity, vascular reactivity and clamp-induced vasodilatation in essential hypertension. Circulation 1996, 96:849-855.
18. Mikhail N, Golub M, Tuck M: Obesity and hypertension. Prog Cardiovasc Dis 1999, 42:39-58.
19. Carr DB, Utzschneider KM, Hull RL, et al.: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III Criteria for the metabolic syndrome. Diabetes 2004, 53:2087-2094.
20. Wildman RP, Munter P, Reynolds K, et al.: The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering. Prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008, 168:1617-1624.
21. Klein S, Fontana L, Young L, et al.: Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004, 350:2549-2557.
22. Thorne A, Lonngvist F, Apelman J, et al.: A pilot study of long-term effects of a novel obesity treatment: Omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 2002, 26:193-199.
23. Csendes A, Maluenda F, Burgos AM: A prospective randomized study comparing patients with morbid obesity submitted to laporotomic gastric bypass with or without omentectomy. Obes Surg 2008 (Epub ahead of print).
24. Stefan N, Kantartzis K, Machann J, et al.: Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008, 168:1609-1616.
25. Petersen KF, Dufour S, Befroy D, et al.: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004, 350:664-671.
26. De Feyter HM, van den Broek NMA, Praet SFE, et al.: Early or advanced stage type 2 diabetes is not accompanied by in vivo skeletal muscle mitochondrial dysfunction. Eur J Endocrinol 2008, 158:643-653.